Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 6/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | GAA | P10253 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | LDHB | P07195 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417803 | 1.00 | HTT (0.49) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL12126890 | 1.00 | HTT (0.49) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL15623485 | 0.90 | HTT (0.49) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL15618724 | 0.90 | HTT (0.49) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL16189751 | 0.90 | NPC1 (0.50) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL23030168 | 0.90 | HTT (0.49) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL28998621 | 0.89 | HTT (0.48) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL4158338 | 0.88 | L3MBTL1 (0.38) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL28692829 | 0.87 | MAPT (0.56) | HTTNPC1RAB9AKMT2AL3MBTL1 | |
| SCHEMBL16204410 | 0.87 | MAPT (0.44) | HTTNPC1RAB9AKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015162622-A1 | PROCESS FOR PREPARATION OF LINEZOLID | VIRDEV INTERMEDIATES PVT. LTD. (IN) | 2015-10-29 | — | — | WO | claimed |
| EP-2595968-B1 | NOVEL PROCESS FOR PREPARATION OF LINEZOLID AND ITS NOVEL INTERMEDIATES | LEE PHARMA LTD (IN) | 2015-09-09 | — | — | EP | claimed |
| EP-1768967-B1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LTD (IN) | 2009-04-22 | — | — | EP | claimed |
| EP-1737850-B1 | A NOVEL PROCESS FOR THE PREPARATION OF LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LTD (IN) | 2007-10-03 | — | — | EP | claimed |
| US-RE47606-E1 | Process for the preparation of linezolid | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2019-09-17 | — | — | US | disclosed |
| US-9643939-B1 | Process for the preparation of linezolid | OPTIMUS DRUGS PRIVATE LIMITED (US) | 2017-05-09 | — | — | US | disclosed |
| US-9643939-B1 | Process for the preparation of linezolid | OPTIMUS DRUGS PRIVATE LIMITED (US) | 2017-05-09 | — | — | US | disclosed |
| US-9593104-B2 | Process for the preparation of oxazolidinone derivatives | BENOVA LABS PVT. LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-9593104-B2 | Process for the preparation of oxazolidinone derivatives | BENOVA LABS PVT. LIMITED (IN) | 2017-03-14 | — | — | US | disclosed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| US-9586913-B2 | Processes for the preparation of linezolid using novel intermediates | SYMED LABS LIMITED (IN) | 2017-03-07 | — | — | US | disclosed |
| WO-2010084514-A2 | A PROCESS FOR THE PREPARATION OF (5S)-(N)-[[3-[3-FLUORO-4-(4-MORPHOLINYL) PHENYL]-2-OXO-5-OXAZOLIDINYL] METHYL] ACETAMIDE | NEULAND LABORATORIES LTD. (IN) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010084514-A2 | A PROCESS FOR THE PREPARATION OF (5S)-(N)-[[3-[3-FLUORO-4-(4-MORPHOLINYL) PHENYL]-2-OXO-5-OXAZOLIDINYL] METHYL] ACETAMIDE | NEULAND LABORATORIES LTD. (IN) | 2010-07-29 | — | — | WO | disclosed |
| EP-1768967-B1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LTD (IN) | 2009-04-22 | — | — | EP | disclosed |
| US-7429661-B2 | Intermediates for linezolid and related compounds | SYMED LABS LIMITED (IN) | 2008-09-30 | — | — | US | disclosed |
| US-7307163-B2 | Process for the preparation of linezolid and related compounds | SYMED LABS LIMITED (IN) | 2007-12-11 | — | — | US | disclosed |
| EP-1768967-A1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | Symed Labs Limited (IN) | 2007-04-04 | — | — | EP | disclosed |
| US-20060247435-A1 | Novel intermediates for linezolid and related compounds | HETERO USA, INC. (US) | 2006-11-02 | — | — | US | disclosed |
| WO-2006008754-A1 | NOVEL INTERMEDIATES FOR LINEZOLID AND RELATED COMPOUNDS | SYMED LABS LIMITED (IN) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247435-A1 | Novel intermediates for linezolid and related compounds | HPD, PTMS, HDAC5 | HTT 2477/4885NPC1 4335/4885RAB9A 2643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.